BOLERO-2 study of Afinitor in ER+HER-2 advanced Breast Cancer is presented at EMCC congress

A pivotal Phase III study-BOLERO-2 examined the safety and efficacy of Afinitor (everolimus) from Novartis in combination with exemestane versus exemestane alone in postmenopausal women with ER+HER2- advanced breast cancer who recurred or progressed while on or following previous treatment with hormonal therapies, letrozole or anastrozole. BOLERO-2 results show Afinitor plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.These reults were initially announced in July 2011 and now are presented at the European Multidisciplinary Cancer Congress 2011.see Baselga J. Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: results of the BOLERO-2 phase III trial. 2011 European Multidisciplinary Cancer Congress. Presentation of late breaking abstract No. 9LBA. September 26, 2011. "Everolimus is the first drug to show significant efficacy when combined with hormonal therapy in women with ER+HER2- advanced breast cancer, where there